CVC ups Recordati take-private offer to €10.5bn after shareholder pushback
TOP STORY: CVC Capital Partners has increased its offer to take Italian pharmaceutical company Recordati private to €10.5bn ($11.8bn), responding to criticism from minority shareholders that its original proposal undervalued the business, according to a report by Bloomberg.
Italian private equity firm CVC Capital Partners has raised its take-private offer for pharmaceutical company Recordati to €10.5 billion ($11.8 billion), according to Bloomberg. The increase comes after minority shareholders criticized the original €51.29 share price as undervaluing the business. CVC and investment partner Groupe Bruxelles Lambert have raised their cash consideration to €53 per share, with the offer now deemed final.
CVC, which already owns nearly half of Recordati, agreed to acquire the remaining shares with GBL in May, with the goal of delisting the company. The board initially backed the original offer in July, but independent directors opposed it, arguing the price was financially inadequate. Activist investor Palliser Capital had urged the board to withdraw its support unless the offer was raised to €60 per share.
Despite the revised proposal, some analysts, such as Paola Saglietti of Banca Akros, still found the €53 offer unattractive and not reflective of Recordati's value and growth potential. Recordati's shares rose to as much as 1.8% to €53.15 following the announcement, having previously traded above €46. The acceptance period for the offer has been extended by eight days until October 23.
CVC acquired a controlling stake in Recordati from its founding family in 2018 for around €3 billion and initiated talks for strategic options in 2024.
Rewritten by urgent.news; may contain errors — check the original.